Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic Classification and Individualized Prognosis in Multiple Myeloma.
Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F, Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O. Maura F, et al. Among authors: papadimitriou m. J Clin Oncol. 2024 Apr 10;42(11):1229-1240. doi: 10.1200/JCO.23.01277. Epub 2024 Jan 9. J Clin Oncol. 2024. PMID: 38194610 Free PMC article.
Impact of rare structural variant events in newly diagnosed multiple myeloma.
Chojnacka M, Diamond B, Ziccheddu B, Rustad E, Maclachlan K, Papadimitriou M, Boyle EM, Blaney P, Usmani S, Morgan G, Landgren O, Maura F. Chojnacka M, et al. Among authors: papadimitriou m. bioRxiv [Preprint]. 2023 Jan 3:2023.01.03.522573. doi: 10.1101/2023.01.03.522573. bioRxiv. 2023. Update in: Clin Cancer Res. 2024 Feb 1;30(3):575-585. doi: 10.1158/1078-0432.CCR-23-1045 PMID: 36711679 Free PMC article. Updated. Preprint.
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.
Ziccheddu B, Giannotta C, D'Agostino M, Bertuglia G, Saraci E, Oliva S, Genuardi E, Papadimitriou M, Diamond B, Corradini P, Coffey D, Landgren O, Bolli N, Bruno B, Boccadoro M, Massaia M, Maura F, Larocca A. Ziccheddu B, et al. Among authors: papadimitriou m. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23299287. doi: 10.1101/2023.12.04.23299287. medRxiv. 2023. Update in: Blood Cancer J. 2024 Jul 19;14(1):117. doi: 10.1038/s41408-024-01096-6 PMID: 38106151 Free PMC article. Updated. Preprint.
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.
Kazandjian D, Diamond B, Papadimitriou M, Hill E, Sklavenitis-Pistofidis R, Ziccheddu B, Blaney P, Chojnacka M, Durante M, Maclachlan K, Young R, Usmani S, Davies F, Getz G, Ghobrial I, Korde N, Morgan G, Maura F, Landgren O. Kazandjian D, et al. Among authors: papadimitriou m. Clin Cancer Res. 2024 Oct 1;30(19):4482-4490. doi: 10.1158/1078-0432.CCR-24-0210. Clin Cancer Res. 2024. PMID: 38652812
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.
Ziccheddu B, Giannotta C, D'Agostino M, Bertuglia G, Saraci E, Oliva S, Genuardi E, Papadimitriou M, Diamond B, Corradini P, Coffey D, Landgren O, Bolli N, Bruno B, Boccadoro M, Massaia M, Maura F, Larocca A. Ziccheddu B, et al. Among authors: papadimitriou m. Blood Cancer J. 2024 Jul 19;14(1):117. doi: 10.1038/s41408-024-01096-6. Blood Cancer J. 2024. PMID: 39030183 Free PMC article.
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma.
Maura F, Kaddoura M, Poos AM, Baughn LB, Ziccheddu B, Bärtsch MA, Cirrincione A, Maclachlan K, Chojnacka M, Diamond B, Papadimitriou M, Blaney P, John L, Reichert P, Huhn S, Gagler D, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Rajkumar SV, Kumar S, Usmani S, Landgren O, Raab MS, Weinhold N. Maura F, et al. Among authors: papadimitriou m. bioRxiv [Preprint]. 2024 Sep 4:2024.08.30.610457. doi: 10.1101/2024.08.30.610457. bioRxiv. 2024. PMID: 39282268 Free PMC article. Preprint.
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma.
Lee H, Durante M, Skerget S, Vishwamitra D, Benaoudia S, Ahn S, Poorebrahim M, Barakat E, Jung D, Leblay N, Ziccheddu B, Diamond B, Papadimitriou M, Cohen AD, Landgren O, Neri P, Maura F, Bahlis NJ. Lee H, et al. Among authors: papadimitriou m. Blood. 2024 Dec 19;144(25):2637-2651. doi: 10.1182/blood.2024026212. Blood. 2024. PMID: 39321344 Free article.
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies.
Diamond B, Chahar D, Jain MD, Poos AM, Durante M, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan K, Jelinek T, Davies F, Figura NB, Morgan G, Mai E, Weisel KC, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Diamond B, et al. Among authors: papadimitriou m. bioRxiv [Preprint]. 2024 Nov 18:2024.11.15.623836. doi: 10.1101/2024.11.15.623836. bioRxiv. 2024. PMID: 39605649 Free PMC article. Preprint.
138 results